Obstetrics & Gynaecology

Cervical Screening, Gynaecological Cancers and Breast Disease in the AMC MCQ

This page explains how the AMC MCQ exam tests the National Cervical Screening Program, the gynaecological cancers and breast disease, all of which follow distinctly Australian pathways. You get the screening algorithm, red-flag presentations, the triple test, familial risk, worked questions and a study plan.

Most tested
HPV result pathways, symptomatic women, postmenopausal bleeding, ovarian mass work-up, triple test
Guideline to know
National Cervical Screening Program clinical guidelines (updated 2025); BreastScreen Australia; Cancer Council optimal care pathways
Classic trap
Offering a screening test to a woman with postcoital bleeding instead of investigating her symptoms
Study time
8–10 hours

What the AMC tests here

Questions in this area come in two kinds. Screening questions give an asymptomatic woman and a test result, and ask what to do next: repeat in five years, repeat in 12 months, refer to colposcopy or something else. Symptom questions give a woman with bleeding, a pelvic mass, a vulval lesion or a breast lump, and ask for the most appropriate investigation or referral.

The most common error is mixing the two. Screening is for people without symptoms. A woman with postcoital bleeding, postmenopausal bleeding or a breast lump needs diagnostic assessment, not a screening test. The AMC places screening options next to diagnostic ones to see whether you can tell the difference.

Australian screening programs differ from those in many other countries. Cervical screening is a primary HPV test every five years from 25 to 74, with self-collection available to everyone eligible. Breast screening invites women aged 50 to 74 for two-yearly mammograms. There is no screening program for ovarian or endometrial cancer.

  • Screening: asymptomatic, follow the program pathway
  • Symptoms: investigate and refer, regardless of screening history
  • Lead-ins: next step, most appropriate investigation, most appropriate referral, correct advice

The National Cervical Screening Program

Since 2017, Australia has used a five-yearly cervical screening test that detects oncogenic HPV, replacing the two-yearly Pap smear. Women and people with a cervix aged 25 to 74 who have ever been sexually active are eligible, including those who have been vaccinated against HPV. People aged 70 to 74 with a negative HPV result can exit the program. Since July 2022, everyone eligible can choose to collect their own vaginal sample, which is tested for HPV only and is as accurate as a clinician-collected sample for HPV detection.

The next step depends on the HPV result. HPV not detected means return in five years. HPV 16 or 18 detected means direct referral for colposcopy, whatever the cytology shows. Oncogenic HPV other than 16 or 18 needs liquid-based cytology (LBC): this is done on the same sample if a clinician collected it, or a clinician-collected sample is needed if the person self-collected. If the LBC is negative or low grade, the person is at intermediate risk and has a repeat HPV test in 12 months. If the LBC shows a possible or definite high-grade lesion, refer to colposcopy.

At the 12-month repeat, HPV not detected returns the person to five-yearly screening, while persistent HPV leads to colposcopy. Some higher-risk groups go to colposcopy sooner rather than waiting 12 months, so follow the guideline for people who are overdue for screening or immune-deficient. Immune-deficient people are screened every three years. The 2025 guideline update made changes to follow-up after treatment: people treated for high-grade lesions have annual HPV tests (test of cure) until two consecutive negative results, then return to routine screening.

  • Age 25 to 74, every 5 years, HPV test
  • Self-collection available to all eligible people; it tests for HPV only
  • HPV 16/18: colposcopy
  • Other oncogenic HPV plus negative or low-grade LBC: repeat HPV in 12 months
  • Other oncogenic HPV plus high-grade LBC: colposcopy
  • Immune-deficient: 3-yearly screening
  • Screening can be done in pregnancy; vaccinated people still screen

Cervical cancer and symptomatic women

Cervical cancer is caused by persistent oncogenic HPV infection. Most cases in Australia now occur in people who are under-screened or have never been screened. Early cancer may be asymptomatic. Symptoms include postcoital bleeding, intermenstrual bleeding, postmenopausal bleeding, unusual discharge and, later, pelvic pain or symptoms of local spread.

Symptomatic women do not follow the screening pathway. A woman with abnormal bleeding should have a speculum examination to look at the cervix and a co-test (HPV and LBC) collected by a clinician, not a self-collected sample. A visible suspicious lesion needs urgent referral to a gynaecologist or gynaecological oncologist regardless of test results. Persistent unexplained postcoital bleeding needs referral even if tests are normal.

Treatment depends on stage: early disease is treated with surgery, and more advanced disease with chemoradiation. Australia has a national strategy to eliminate cervical cancer as a public health problem by 2035, based on HPV vaccination through the school program, five-yearly HPV screening with self-collection, and treatment. The HPV vaccine is given as a single dose in the school program, at around 12 to 13 years.

  • Postcoital bleeding: speculum, clinician-collected co-test, refer if persistent or a lesion is seen
  • Visible cervical lesion: refer urgently, even if the screening test was normal
  • Never-screened women: higher risk; encourage screening, including self-collection
  • HPV vaccination: single dose in the school program

Endometrial, ovarian and vulval cancer

Endometrial cancer typically presents with postmenopausal bleeding, which is never normal and must be investigated. Risk factors relate to unopposed oestrogen: obesity, PCOS with long anovulatory cycles, nulliparity, late menopause, oestrogen-only therapy in a woman with a uterus, tamoxifen and Lynch syndrome. Diabetes and hypertension also raise risk. The first investigation for postmenopausal bleeding is transvaginal ultrasound to measure endometrial thickness. A thickened endometrium (more than 4 mm in a woman not on MHT is a commonly used threshold), or persistent bleeding even with a thin endometrium, needs hysteroscopy and endometrial biopsy. Treatment is usually total hysterectomy and bilateral salpingo-oophorectomy.

Ovarian cancer often presents late with vague, persistent symptoms: abdominal bloating or distension, early satiety, pelvic or abdominal pain, urinary frequency and change in bowel habit. A woman with these symptoms that are new and persistent, especially over 50, should have a pelvic ultrasound (transvaginal and transabdominal) and a serum CA-125. A complex mass, ascites or a raised CA-125 in a postmenopausal woman needs urgent referral to a gynaecological oncologist. There is no effective screening test for ovarian cancer in average-risk women, so CA-125 and ultrasound screening are wrong answers for an asymptomatic woman. Women with BRCA1 or BRCA2 pathogenic variants are offered risk-reducing salpingo-oophorectomy after childbearing, at an age that depends on the gene.

Vulval cancer mainly affects older women. It presents with persistent itch, a lump or ulcer, bleeding or pain. Lichen sclerosus (white, atrophic skin with loss of architecture) increases the risk and is treated with a potent topical corticosteroid and long-term review. Any persistent or suspicious vulval lesion needs a biopsy. A new Bartholin gland mass in an older woman also needs biopsy.

  • Postmenopausal bleeding: transvaginal ultrasound, then hysteroscopy and biopsy if thickened or persistent
  • Tamoxifen: increases endometrial cancer risk; investigate any bleeding
  • Persistent bloating and early satiety over 50: ultrasound and CA-125
  • No ovarian cancer screening for average-risk women
  • Lichen sclerosus: potent topical steroid, long-term follow-up, biopsy suspicious areas
  • Lynch syndrome: risk of endometrial, ovarian and colorectal cancer

Breast screening, familial risk and breast lumps

BreastScreen Australia actively invites women aged 50 to 74 for a free mammogram every two years. Women aged 40 to 49 and 75 and over are eligible to attend but are not actively invited. Screening is for women without symptoms. A woman with a breast lump, skin change or nipple change needs diagnostic assessment through her GP, not a screening appointment.

Familial risk is assessed using family history: the number of affected relatives, their age at diagnosis, ovarian cancer in the family, male breast cancer, Ashkenazi Jewish ancestry and known gene variants. Most women with a family history are at or slightly above average risk and follow population screening. Women at high risk are referred to a family cancer clinic for genetic testing and may have earlier and more intensive surveillance, including MRI. Cancer Australia and eviQ provide Australian risk categories.

The triple test is the standard for investigating any breast lump: clinical examination, imaging and non-surgical biopsy (usually core biopsy). Under 35, ultrasound is the first imaging test because breast tissue is dense. From 35, use mammography plus ultrasound. The lump is considered benign only if all three components are benign. Common benign conditions include fibroadenoma (mobile, firm, young women), cysts (smooth, often around menopause, aspirated if symptomatic), fat necrosis (after trauma), duct ectasia and intraductal papilloma (bloody nipple discharge). Breast cancer can present as a hard irregular lump, skin dimpling, nipple inversion, peau d'orange, eczema-like change of the nipple (Paget disease) or an inflamed breast that does not settle with antibiotics (inflammatory breast cancer).

  • BreastScreen: invited 50–74, two-yearly; eligible from 40
  • Symptomatic women: diagnostic imaging, not BreastScreen
  • Triple test: examination, imaging, core biopsy
  • Under 35: ultrasound first; 35 and over: mammogram plus ultrasound
  • Nipple eczema not responding to treatment: biopsy for Paget disease
  • Mastitis in a non-lactating woman that does not settle: triple test

Australian differences to know

Overseas-trained doctors often answer from older Pap smear rules or from programs in their home country. Use the Australian rules below in the exam.

  • Cervical screening: HPV test every 5 years from 25 to 74, not 3-yearly cytology
  • Self-collection available to every eligible person, not only under-screened people
  • HPV 16/18 goes straight to colposcopy
  • Elimination target for cervical cancer by 2035
  • Single-dose HPV vaccine in the school program
  • BreastScreen invites women 50–74 every two years
  • No ovarian or endometrial cancer screening program

How to approach screening and cancer stems

Ask first: does she have symptoms? If yes, investigate and refer; ignore the screening interval. If no, find her age, the last screening result and any risk group, then follow the program pathway exactly.

For cervical results, read the HPV type first, then the cytology. For bleeding after menopause, think endometrial cancer and start with transvaginal ultrasound. For a pelvic mass, check menopausal status, ultrasound features and CA-125. For a breast lump, apply the triple test with the age-appropriate imaging.

  • Asymptomatic with normal HPV 3 years ago: next test in 2 years, not now
  • Postcoital bleeding at 32 with negative HPV last year: speculum and co-test, refer if persistent
  • Bleeding on tamoxifen: transvaginal ultrasound and hysteroscopy
  • Breast lump at 28: ultrasound and biopsy if needed, not mammogram first
Screening results and presentations with the expected next step
SituationFindingNext step
Routine cervical screenHPV not detectedRepeat in 5 years
Routine cervical screenHPV 16/18 detectedRefer for colposcopy
Routine cervical screenOther HPV, LBC negative or low gradeRepeat HPV in 12 months
Routine cervical screenOther HPV, LBC high gradeRefer for colposcopy
Self-collected sampleOther HPV detectedClinician-collected LBC
Postcoital bleedingAny screening historySpeculum, clinician co-test, refer if persistent or lesion seen
Postmenopausal bleedingEndometrium thickenedHysteroscopy and endometrial biopsy
Bloating and early satiety, age 58Persistent new symptomsPelvic ultrasound and CA-125
Breast lump, age 28Mobile smooth lumpTriple test with ultrasound first
Asymptomatic woman, 52Due for breast screeningBreastScreen mammogram, two-yearly

Worked examples in AMC style

Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for cervical screening & gynae cancers.

Example 1

A 34-year-old woman has a routine clinician-collected cervical screening test. The result shows oncogenic HPV (not 16/18) detected, with liquid-based cytology reported as low-grade squamous intraepithelial lesion (LSIL). Her previous screen five years ago was normal. She is well and has no symptoms.

What is the most appropriate next step?

Show answer and reasoning

Answer: B. Repeat the HPV test in 12 months' time

  • A. Colposcopy is for HPV 16/18 or high-grade cytology, not other HPV with low-grade changes on a first result.
  • B. Other oncogenic HPV with negative or low-grade cytology is intermediate risk. Repeat the HPV test in 12 months; most infections clear.
  • C. An HPV-positive result cannot be managed as routine.
  • D. Six-monthly cytology is from the old Pap smear program.
  • E. Treatment without colposcopic assessment and histology is not indicated.

Non-16/18 HPV with negative or low-grade LBC: repeat HPV in 12 months.

Based on: National Cervical Screening Program clinical guidelines

Example 2

A 61-year-old woman has had two episodes of light vaginal bleeding in the past month. Her menopause was at 52 and she has never used MHT. She takes tamoxifen after treatment for breast cancer two years ago. Her BMI is 34 kg/m2. Speculum examination shows a normal cervix and her cervical screening test last year was negative.

What is the most appropriate next step?

Show answer and reasoning

Answer: D. Transvaginal ultrasound of the endometrium

  • A. Cervical screening does not assess the endometrium; postmenopausal bleeding must be investigated.
  • B. Stopping tamoxifen is an oncology decision and does not investigate the bleeding.
  • C. Treating presumed atrophy without excluding cancer is unsafe.
  • D. Postmenopausal bleeding with tamoxifen and obesity raises the risk of endometrial cancer. Transvaginal ultrasound is the first step, followed by hysteroscopy and biopsy; with tamoxifen, many units go straight to hysteroscopy.
  • E. CA-125 is for suspected ovarian cancer and is not the test for postmenopausal bleeding.

Postmenopausal bleeding is never normal: transvaginal ultrasound, then hysteroscopy and biopsy.

Based on: Cancer Council optimal care pathway for endometrial cancer; RANZCOG guidance

Example 3

A 27-year-old woman presents with a 2 cm smooth, mobile, non-tender lump in the upper outer quadrant of her right breast, noticed 3 weeks ago. It has not changed through her cycle. There is no nipple discharge or skin change. She has no family history of breast or ovarian cancer.

What is the most appropriate next step?

Show answer and reasoning

Answer: B. Breast ultrasound, biopsy if needed

  • A. Mammography is less useful in dense young breasts, and screening is not for symptomatic women.
  • B. Under 35, ultrasound is the first imaging test in the triple test, with core biopsy if the lump is not clearly a simple cyst.
  • C. It is probably a fibroadenoma, but the diagnosis needs the triple test.
  • D. Excision is not the first step and is often unnecessary for confirmed fibroadenomas.
  • E. The lump has persisted through a cycle already; it needs imaging now.

Breast lump under 35: triple test starting with ultrasound.

Based on: Cancer Australia: Investigation of a new breast symptom

Quick recall

Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.

Where candidates lose marks

  • Screening a symptomatic woman

    Bleeding or a lump needs diagnostic investigation and referral, not a screening test.

  • Old Pap smear rules

    Two-yearly cytology and starting at 18 no longer apply in Australia.

  • Screening for ovarian cancer

    CA-125 and ultrasound are not used for average-risk women without symptoms.

  • Mammogram first under 35

    Ultrasound is the first-line imaging for young women.

  • Self-collection for symptoms

    Symptomatic women need a clinician-collected co-test and examination.

How to study cervical screening & gynae cancers

  1. Day 1: The NCSP pathway; draw the HPV result flowchart from memory and practise 10 result scenarios.

  2. Day 2: Cervical cancer, symptomatic women, HPV vaccination and the 2035 elimination strategy.

  3. Day 3: Endometrial cancer and postmenopausal bleeding; ovarian masses and CA-125; BRCA and Lynch.

  4. Day 4: Vulval disease and cancer; then breast screening, familial risk and the triple test.

  5. Day 5: 25 mixed questions; check each wrong answer against the table on this page.

Practise cervical screening & gynae cancers free

Cervical screening & gynae cancers: questions candidates ask

Do HPV-vaccinated women still need cervical screening?

Yes. The vaccine does not cover every oncogenic HPV type and many adults were vaccinated after exposure. Vaccinated people follow the same five-yearly program.

Can a pregnant woman have cervical screening?

Yes. Screening can be done in pregnancy if she is due or overdue, and the program supports both clinician-collected and self-collected samples.

Is CA-125 a screening test?

No. It is used with ultrasound to assess women with symptoms or a pelvic mass. It is raised in many benign conditions, especially in premenopausal women.

When can a woman stop cervical screening?

Between 70 and 74, with a negative HPV result at her exit test. Women who have never been screened can request a test after 74.

Why is postmenopausal bleeding always investigated?

A proportion of women with postmenopausal bleeding have endometrial cancer, which is curable when found early. Transvaginal ultrasound and, if needed, hysteroscopy and biopsy find it.

Practise cervical screening & gynae cancers until the decisions are automatic

Free account, 50 questions, full explanations. Upgrade only if it helps.